ANABASE.
Top Line : What are the real-world outcomes from modern therapy for anal squamous cell carcinoma? The Study : While the overall treatment paradigm for anal squamous cell carcinoma has been well established for many years, there have been significant advances in imaging and radiation techniques. How have these advances impacted treatment outcomes over time? FFCD-ANABASE is a large, prospective, multicenter observational cohort study from France that collected data on 1015 patients treated for anal SCC from 2015 to 2020. The majority were female (75.6%) and had workup with PET/CT (73%) and MRI (71.2%). Just over half (56.7%) had locally advanced disease (T3-4 or N+) with the rest having early stage disease (T1-2 N0). Most were also treated with IMRT (80.3%) and concurrent mitomycin and 5FU. The median total dose to the primary tumor was 60Gy with over a third of patients in both the early and advanced groups receiving >60Gy. These total doses are important to note as they underlin